Keap1-Nrf2-IN-18

• UNSPSC Description:

  Keap1-Nrf2-IN-18 (Compound 22) is an orally active Keap1-Nrf2 protein-protein interaction (PPI) inhibitor with good pharmacokinetics (PK) profiles and more potent in vivo activities in rats. Keap1-Nrf2-IN-18 has the strongest inhibitory activity in structure−activity relationship (SAR) study (KD = 0.0029 μM)[1].

• Target Antigen:

  Keap1-Nrf2

• Type:

  Reference compound

• Related Pathways:

  NF-κB

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/keap1-nrf2-in-18.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CC1=CC=C([C@@H](NC([C@H](C2=CC=C(CC3=NC=CC=C3OCC)C=C2)F)=O)[C@@H](C)C(O)=O)C=C1

• Molecular Weight:

  464.53

• References & Citations:

  [1]Otake K, et al. Optimization Efforts for Identification of Novel Highly Potent Keap1-Nrf2 Protein-Protein Interaction Inhibitors. J Med Chem. 2024 Feb 26.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported